Clinical inquiries. Does warfarin prevent venous thromboembolic events in aPL-positive patients?
Mazzone
Michael F
MF
Waukesha Family Medicine Residency Program, Waukesha, USA.
Jamieson
Barbara
B
Lo
Vincent
V
D000328:Adult; D000367:Age Factors; D017152:Antibodies, Antiphospholipid / Q000276:immunology*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D005194:Family Practice; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000175:diagnosis* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D013923:Thromboembolism / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome; D014859:Warfarin / Q000008:administration & dosage*
D017152:Antibodies, Antiphospholipid; D014859:Warfarin